Cargando…

Pembrolizumab in bacillus Calmette-Guérin unresponsive nonmuscle-invasive bladder cancer; a difficult to treat disease (KEYNOTE-057)

Detalles Bibliográficos
Autor principal:	Kumar, Bhuwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555576/ https://www.ncbi.nlm.nih.gov/pubmed/34759534 http://dx.doi.org/10.4103/iju.iju_244_21

Ejemplares similares

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: A pilot study
por: Vasudeva, Pawan, et al.
Publicado: (2008)

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
por: Pandey, Abhishek
Publicado: (2022)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis
por: Broughton, Edward I., et al.
Publicado: (2022)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
por: Suh, Jungyo, et al.
Publicado: (2021)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials
por: Quan, Yongjun, et al.
Publicado: (2017)

Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations
por: Wroclawski, Marcelo Langer, et al.
Publicado: (2019)

What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

T1 bladder cancer on restaging transurethral resection should be treated with immediate cystectomy
por: Gautam, Gagan, et al.
Publicado: (2007)

Low-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Shuxiong, et al.
Publicado: (2015)

Patient Preferences for Treatment of Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
por: Collacott, Hannah, et al.
Publicado: (2023)

Relevance of inflammatory pseudotumor associated with bladder tumor
por: Kurien, Annamma, et al.
Publicado: (2007)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

Intravesical real-time imaging and staging of bladder cancer: Use of optical coherence tomography
por: Sengottayan, Vengatesh K., et al.
Publicado: (2008)

Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
por: Mohamed, Mohamed Bakr, et al.
Publicado: (2020)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
por: Kumaraswamy, Santosh
Publicado: (2021)

A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
por: Kulkarni, Girish S., et al.
Publicado: (2022)

Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer
por: Jamil, Marcus L, et al.
Publicado: (2019)

Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette–Guérin therapy
por: Nakamura, Ryohta, et al.
Publicado: (2023)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size
por: Prakash, Gagan, et al.
Publicado: (2007)

Monthly maintenance protocol Bacillus Calmette–Guerin as a viable alternative to Southwest Oncology Group maintenance protocol in nonmuscle-invasive bladder cancer: A prospective randomized study
por: Gupta, Naveen Kumar, et al.
Publicado: (2020)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer
por: Rachakonda, Tara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0gb7e37nd0l1g5krcp71i45cgp